ICPT - Intercept Pharma settles with Apotex over Ocaliva patents

• Intercept Pharmaceuticals ( NASDAQ: ICPT ) and Apotex reached a settlement in regards to patent claims against Apotex over Intercept's rate liver disease treatment Ocaliva. Intercept ticked up 0.7%.
• The settlement was disclosed in a Delaware court filing on Friday.
• The settlement comes as Intercept was set to battle with Apotex and MSN Laboratories in court on Monday over the patent claims. Apotex and MSN Labs were the last remaining defendants in the case.
• Last month generic drugmaker Amneal Pharmaceuticals ( AMRX ) to settle a patent dispute over the liver disease therap y Ocaliva with Intercept ( ICPT ).

For further details see: